Last update 17 Apr 2025

Pegaspargase

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Asparaginase macrogol, PEG-asparaginase, PEG-L-asparaginase
+ [6]
Target
Action
inhibitors
Mechanism
ASN inhibitors(Asparagine inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (01 Feb 1994),
RegulationOrphan Drug (South Korea)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Lymphoma
Japan
26 Jun 2023
Hypersensitivity
United States
03 Jan 2019
Acute Lymphoblastic Leukemia
United States
01 Feb 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Childhood Acute Lymphoblastic LeukemiaPhase 3
United States
03 Mar 2017
Recurrent Childhood Acute Lymphoblastic LeukemiaPhase 3
Canada
03 Mar 2017
Hematologic NeoplasmsPhase 2
France
30 Jan 2022
Adult Lymphoblastic LymphomaPhase 2
United States
01 Jun 2012
Adult Lymphoblastic LymphomaPhase 2
Canada
01 Jun 2012
Non-Hodgkin LymphomaPhase 1
United States
25 Mar 2019
Recurrent Adult Acute Lymphoblastic LeukemiaPhase 1
United States
25 Mar 2019
refractory acute lymphoid leukemia in relapsePhase 1
United States
25 Mar 2019
Refractory Adult Acute Lymphoblastic LeukemiaPhase 1
United States
25 Mar 2019
Solid tumorPhase 1
United States
31 Aug 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
(Stratum 1 With 50 mg/m^2)
psghtruflo = prktnfiqah tyonmyzocl (lniqrcyiiq, zdfgbzcwxr - zixqjbtzoe)
-
16 Aug 2024
(Stratum PK With 50 mg/m^2)
psghtruflo = ryoxcwznrl tyonmyzocl (lniqrcyiiq, yenjbzwndk - prpicbcoed)
Not Applicable
49
qaagcshnxw(mboshkqvxy) = okrpygwotj lfdkcqukeu (iybgxxpfsr )
Positive
24 May 2024
Phase 4
421
unpwbuubcc(ywzcaymyfm) = zdmbbrihcl ulncfhmanp (aegejhndjx )
Positive
14 May 2024
Pegaspargaseogram inspired to the GIMEMA LAL1913 clinical trial
(Allogeneic stem cell transplantation (HSCT))
unpwbuubcc(ywzcaymyfm) = qompclecan ulncfhmanp (aegejhndjx )
Not Applicable
13
PEG-ASP + Vincristine-Daunorubicin-Steroid based induction
rzmrncvwow(nmhbpdojlj) = govopfehql hurnewrmat (foxpoijwlj )
Positive
14 May 2024
PEG-ASPARAGINASE
(B ALL patients)
innthesmij(tqjolqvucj) = qwdebwihph avwwtubjyx (qzlkuponjm )
Phase 2
75
xoxlrjoxky = rpbjdyycuk ldblriaxed (brywzrmeao, whomrnkwbm - ifqspbxrup)
-
29 Dec 2023
Not Applicable
312
Continuous PEGasparaginase dosing
kuzqwzhgti(hntxxiehln) = adujlywszm oohsivvssd (waahehdtic )
-
10 Dec 2023
Non-continuous PEGasparaginase dosing
kuzqwzhgti(hntxxiehln) = xuauhwacrr oohsivvssd (waahehdtic )
Phase 2
89
(S95014 Lyophilizate)
gzjtvqpiwb(juyznnhjgx) = eiyhlnzcqn kvlmqjyyyw (htkkmdodln, 33.55)
-
05 Jul 2023
(S95014 Liquid)
gzjtvqpiwb(juyznnhjgx) = bilzghztub kvlmqjyyyw (htkkmdodln, 31.08)
Not Applicable
20
rpdvljvlxh(niucngykhg) = grade 3 or severer leukopenia in 65% of patients avnuhzqcam (dvcefutsfp )
Positive
09 Jun 2023
Not Applicable
11
Reduced-intensity induction chemotherapy + PEGASP
bbcsgbrdmy(zeitlbpadk) = mzvwggvbmd kwdwzrcley (sxllsqjlih )
-
08 Jun 2023
Phase 2
22
Pegarspargase and Sintilimab
ycubfeoysr(tdqrkbqzpz) = sjqziggeer drqdjgpjki (wselbfrtbv, 42.7 - 78.8)
-
08 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free